Newsletter
Subcutaneous Tirzepatide for Type 2 Diabetes, Noninvasive Respiratory Strategies for COVID-19 and Acute Hypoxemic Respiratory Failure, Clinical Outcomes 1 Year After ICU Treatment for COVID-19, and more

JAMA Editor’s Summary

Subcutaneous Tirzepatide for Type 2 Diabetes, Noninvasive Respiratory Strategies for COVID-19 and Acute Hypoxemic Respiratory Failure, Clinical Outcomes 1 Year After ICU Treatment for COVID-19, and more

Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the issue.
February 8, 2022

Subcutaneous Tirzepatide for Type 2 Diabetes, Noninvasive Respiratory Strategies for COVID-19 and Acute Hypoxemic Respiratory Failure, Clinical Outcomes 1 Year After ICU Treatment for COVID-19, and more

Editor’s Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the February 8, 2022 issue.

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
Four Authors Untangle When Dad Has Dementia Virtual Q&A on the changes and challenges a dementia diagnosis.